èšåºæ®µéã®ãã€ãªå»è¬åäŒæ¥ã§ãã Abeona Therapeutics Inc. ã¯ãçåœãè
ããåžå°éºäŒæ§çŸæ£ã«å¯ŸããéºäŒåããã³çްèçæ³ãéçºããŠããŸããå瀟ã®äž»èŠããã°ã©ã ã«ã¯ã壿§æ é€é害æ§è¡šç®æ°Žç±çã«å¯Ÿããèªå·±éºäŒåä¿®æ£çްèçæ³ EB-101ããµã³ãã£ãªããçå矀 A åã«å¯Ÿããã¢ããé䌎ãŠã€ã«ã¹ããŒã¹ã®éºäŒåçæ³ ABO-102ããµã³ãã£ãªããçå矀 B åã«å¯Ÿãã AAV ããŒã¹ã®éºäŒåçæ³ ABO-101 ãªã©ããããŸããå瀟ã¯ãŸããCLN3 çŸæ£ã®æ²»çè¬ ABO-201ãå¢èæ§ç·ç¶çã®æ²»çè¬ ABO-401ãéºäŒæ§çŒçŸæ£ã®æ²»çè¬ ABO-5OX ãéçºããŠããŸããããã«ãAIM ãã¯ã¿ãŒ ãã©ãããã©ãŒã ããã°ã©ã ãéã㊠AAV ããŒã¹ã®éºäŒåçæ³ãéçºããŠããŸããå瀟ã¯ä»¥å㯠PlasmaTech Biopharmaceuticals, Inc. ãšããŠç¥ãããŠããŸãããã2015 幎 6 æã« Abeona Therapeutics Inc. ã«ç€Ÿåã倿ŽããŸãããAbeona Therapeutics Inc. 㯠1974 幎ã«èšç«ããããã¥ãŒãšãŒã¯å·ãã¥ãŒãšãŒã¯ã«æ¬ç€Ÿã眮ããŠããŸãã